Evaluation of CD4+:CD8+ Ratio in Patients With Cervical Cancer and the Levels of Inflammatory Markers
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND/AIM: Cervical cancer remains a major public health concern. The ratio of CD4+:CD8+ T-cells is used to evaluate the immune system function. This study aimed to explore the CD4+:CD8+ T-cell ratio in relation to the glycemic status, inflammatory markers, vitamin D, and vitamin B12 in patients with early diagnosed cervical cancer.
PATIENTS AND METHODS: This is a cross-sectional study. Blood samples were collected for flow cytometry analysis. Information regarding Papanicolaou (Pap) smears and colposcopy investigations were collected from 152 women with type 2 diabetes admitted to East Jeddah Hospital, Jeddah, Saudi Arabia, between January 2018 and January 2021.
RESULTS: Patients with early cervical carcinoma and a higher CD4+:CD8+ ratio (>1.2) had a higher C-reactive protein (CRP) level than those with a lower CD4+:CD8+ ratio (Mean±SD=13.75±13.3 vs. 10.85±8.1; p-value=0.034). Patients with early cervical carcinoma, diabetes, and higher CD4+:CD8+ ratio (>1.2) had a higher blood HbA1c percent than those with a lower CD4+:CD8+ ratio.
CONCLUSION: A high CD4+:CD8+ T-cells ratio was associated with an increased HbA1c% and CRP levels in women with diabetes diagnosed with early cervical carcinoma, which can induce inflammation in early diagnosed patients with cervical cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
In vivo (Athens, Greece) - 36(2022), 5 vom: 01. Sept., Seite 2414-2421 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salih, Magdi M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 15.09.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/invivo.12975 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346160391 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346160391 | ||
| 003 | DE-627 | ||
| 005 | 20231226030746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/invivo.12975 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM346160391 | ||
| 035 | |a (NLM)36099148 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salih, Magdi M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of CD4+:CD8+ Ratio in Patients With Cervical Cancer and the Levels of Inflammatory Markers |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a BACKGROUND/AIM: Cervical cancer remains a major public health concern. The ratio of CD4+:CD8+ T-cells is used to evaluate the immune system function. This study aimed to explore the CD4+:CD8+ T-cell ratio in relation to the glycemic status, inflammatory markers, vitamin D, and vitamin B12 in patients with early diagnosed cervical cancer | ||
| 520 | |a PATIENTS AND METHODS: This is a cross-sectional study. Blood samples were collected for flow cytometry analysis. Information regarding Papanicolaou (Pap) smears and colposcopy investigations were collected from 152 women with type 2 diabetes admitted to East Jeddah Hospital, Jeddah, Saudi Arabia, between January 2018 and January 2021 | ||
| 520 | |a RESULTS: Patients with early cervical carcinoma and a higher CD4+:CD8+ ratio (>1.2) had a higher C-reactive protein (CRP) level than those with a lower CD4+:CD8+ ratio (Mean±SD=13.75±13.3 vs. 10.85±8.1; p-value=0.034). Patients with early cervical carcinoma, diabetes, and higher CD4+:CD8+ ratio (>1.2) had a higher blood HbA1c percent than those with a lower CD4+:CD8+ ratio | ||
| 520 | |a CONCLUSION: A high CD4+:CD8+ T-cells ratio was associated with an increased HbA1c% and CRP levels in women with diabetes diagnosed with early cervical carcinoma, which can induce inflammation in early diagnosed patients with cervical cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C-Reactive protein | |
| 650 | 4 | |a Cervical cancer | |
| 650 | 4 | |a diabetic women | |
| 650 | 4 | |a early cervical carcinoma | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 700 | 1 | |a Almehmadi, Mazen |e verfasserin |4 aut | |
| 700 | 1 | |a Shafie, Alaa |e verfasserin |4 aut | |
| 700 | 1 | |a Alsharif, Abdulaziz |e verfasserin |4 aut | |
| 700 | 1 | |a Alsiwiehri, Naif |e verfasserin |4 aut | |
| 700 | 1 | |a El-Askary, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Alzahrani, Khalid |e verfasserin |4 aut | |
| 700 | 1 | |a Aljuaid, Abdulelah |e verfasserin |4 aut | |
| 700 | 1 | |a Abdulaziz, Osama |e verfasserin |4 aut | |
| 700 | 1 | |a Alrehaili, Amani Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Almalki, Abdulraheem A |e verfasserin |4 aut | |
| 700 | 1 | |a Alzahrani, Hassan Swed |e verfasserin |4 aut | |
| 700 | 1 | |a Halawi, Mustafa |e verfasserin |4 aut | |
| 700 | 1 | |a Almalki, Safar |e verfasserin |4 aut | |
| 700 | 1 | |a Alosimi, Ebtisam |e verfasserin |4 aut | |
| 700 | 1 | |a Gharib, Amal F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t In vivo (Athens, Greece) |d 1992 |g 36(2022), 5 vom: 01. Sept., Seite 2414-2421 |w (DE-627)NLM012776912 |x 1791-7549 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:5 |g day:01 |g month:09 |g pages:2414-2421 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/invivo.12975 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 5 |b 01 |c 09 |h 2414-2421 | ||